西达基奥仑赛或标准治疗用于来那度胺难治性多发性骨髓瘤患者的患者报告结局(CARTITUDE-4):随机、开放标签、3期试验结果
CARTITUDE-4研究纳入419例来那度胺难治性复发多发性骨髓瘤患者,随机接受西达基奥仑赛(cilta-cel)或标准治疗。cilta-cel组症状持续加重中位时间23.7个月 vs 标准治疗组18.9个月(HR 0.42;95%CI 0.26-0.68)。EORTC全局健康状况12个月平均变化cilta-cel组+10.1分 vs 标准治疗组-1.5分。
要点
- cilta-cel组症状持续加重中位时间23.7个月,标准治疗组18.9个月(HR 0.42)。
- EORTC全局健康状况12个月平均变化cilta-cel组+10.1分,标准治疗组-1.5分。
- cilta-cel组全局健康状况和EQ-5D-5L视觉模拟量表临床意义改善率高于标准治疗组。
核心结论
- 健康相关生活质量改善和症状加重延迟支持cilta-cel在来那度胺难治性疾病中的临床疗效。
研究设计与样本
- 正在进行的3期、开放标签CARTITUDE-4研究,从美国、欧洲、亚洲和澳大利亚的81个中心招募患者。
- 患者按1:1随机分配至cilta-cel组(目标剂量0.75×10^6 CAR-T细胞/kg)或标准治疗组(达雷妥尤单抗+泊马度胺+地塞米松;泊马度胺+硼替佐米+地塞米松)。
- 符合条件的患者为复发、来那度胺难治性多发性骨髓瘤,既往接受过1-3线治疗(包括蛋白酶体抑制剂和免疫调节剂),ECOG体能状态评分为0或1。
- 2020年7月10日至2021年11月17日入组,筛查516例患者中419例被随机分配(cilta-cel组n=208;标准治疗组n=211;中位随访15.9个月[IQR 12.4-17.8]);中位年龄61岁。
- cilta-cel组208例中191例(92%)和标准治疗组209例可评估患者中190例(91%)完成基线评估。
主要发现
- MySIm-Q基线后依从率cilta-cel组为70%-81%,标准治疗组为79%-89%。
- MySIm-Q症状持续加重中位时间cilta-cel组23.7个月 vs 标准治疗组18.9个月(HR 0.42;95%CI 0.26-0.68)。
- EORTC全局健康状况12个月平均变化cilta-cel组+10.1分(95%CI 7.0-13.1)vs 标准治疗组-1.5分(95%CI -5.3-2.3)。
- EQ-5D-5L视觉模拟量表12个月平均变化cilta-cel组+8.0分(95%CI 5.2-10.7)vs 标准治疗组+1.4分(95%CI -1.9-4.7)。
- 全局健康状况和视觉模拟量表临床意义改善率cilta-cel组高于标准治疗组。
关键数值与推荐
- MySIm-Q症状持续加重中位时间:cilta-cel组23.7个月 vs 标准治疗组18.9个月(HR 0.42;95%CI 0.26-0.68)。
- EORTC全局健康状况12个月平均变化:cilta-cel组+10.1分(95%CI 7.0-13.1)vs 标准治疗组-1.5分(95%CI -5.3-2.3)。
- EQ-5D-5L视觉模拟量表12个月平均变化:cilta-cel组+8.0分(95%CI 5.2-10.7)vs 标准治疗组+1.4分(95%CI -1.9-4.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In CARTITUDE-4, ciltacabtagene autoleucel (cilta-cel) significantly improved progression-free survival (primary endpoint; previously reported) versus standard of care in patients with relapsed, lenalidomide-refractory multiple myeloma. We report here patient-reported outcomes. METHODS: In the ongoing, phase 3, open-label CARTITUDE-4 study, patients were recruited from 81 sites in the USA, Europe, Asia, and Australia, and were randomly assigned 1:1 to cilta-cel (target, 0·75 × 106 CAR-T cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone). Eligible patients had relapsed, lenalidomide-refractory multiple myeloma, received one to three previous treatment lines including a proteasome inhibitor and an immunomodulatory drug, and had an ECOG performance status of 0 or 1. Secondary endpoints reported here include time to sustained worsening of symptoms (Multiple Myeloma Symptom and Impact Questionnaire [MySIm-Q]; a key secondary endpoint) and change in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire Core C30 (intention-to-treat population) and EuroQol 5-Dimension 5-Level (EQ-5D-5L; intention-to-treat population). This study is registered with ClinicalTrials.gov number NCT04181827 and is ongoing. FINDINGS: Patients were enrolled from July 10, 2020, to Nov 17, 2021, and 419 of 516 screened patients were randomly assigned (cilta-cel, n=208; standard of care, n=211; median follow-up, 15·9 months [IQR 12·4 to 17·8]); median age was 61 years. 191 (92%) of 208 patients in the cilta-cel group and 190 (91%) of 209 evaluable patients in the standard- of-care group completed baseline assessments. MySIm-Q compliance post-baseline was 70 to 81% (cilta-cel) and 79 to 89% (standard of care). MySIm-Q median time to sustained symptom worsening with cilta-cel versus standard of care was 23·7 versus 18·9 months (HR 0·42; 95% CI 0·26 to 0·68). 12-month mean changes for EORTC global health status (GHS) were +10·1 (95% CI 7·0 to 13·1) and -1·5 (95% CI -5·3 to 2·3) points and were +8·0 (95% CI 5·2 to 10·7) and +1·4 (95% CI -1·9 to 4·7) points for EQ-5D-5L visual analogue scale (VAS). Rates of clinically meaningful improvements in GHS and VAS were higher with cilta-cel than with standard of care. INTERPRETATION: Health-related QoL improvements and delayed symptom worsening support cilta-cel's clinical efficacy in lenalidomide-refractory disease. FUNDING: Janssen Research & Development, Legend Biotech USA.
引用
- Mina R, Mylin AK, Yokoyama H, et al. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol. 2025. PMID: 39756844. doi:10.1016/S2352-3026(24)00320-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。